Compared to Estimates, Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Key Metrics

Zacks11-06

Ionis Pharmaceuticals (IONS) reported $134 million in revenue for the quarter ended September 2024, representing a year-over-year decline of 6.9%. EPS of -$0.95 for the same period compares to -$1.03 ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481393816?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/AwCmIhR0z9Bg4cEkwuNQjw--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/8442d24e11d454aa89061259a9714d43","is_english":true,"pubTime":"2024-11-06 22:30","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2481393816","market":"us","top_or_hot":-1,"title":"Compared to Estimates, Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Key Metrics","media":"Zacks","content":"<div>\n<p>Ionis Pharmaceuticals (IONS) reported $134 million in revenue for the quarter ended September 2024, representing a year-over-year decline of 6.9%. EPS of -$0.95 for the same period compares to -$1.03 ...</p>\n\n<a href=\"https://finance.yahoo.com/news/compared-estimates-ionis-pharmaceuticals-ions-143026188.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Compared to Estimates, Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Key Metrics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCompared to Estimates, Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Key Metrics\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-06 22:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/compared-estimates-ionis-pharmaceuticals-ions-143026188.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ionis Pharmaceuticals (IONS) reported $134 million in revenue for the quarter ended September 2024, representing a year-over-year decline of 6.9%. EPS of -$0.95 for the same period compares to -$1.03 ...</p>\n\n<a href=\"https://finance.yahoo.com/news/compared-estimates-ionis-pharmaceuticals-ions-143026188.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IONS","symbol_name":"Ionis Pharmaceuticals, Inc","start_time":0,"source_url":"https://finance.yahoo.com/news/compared-estimates-ionis-pharmaceuticals-ions-143026188.html","article_id":"2481393816","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/AwCmIhR0z9Bg4cEkwuNQjw--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/8442d24e11d454aa89061259a9714d43"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481393816","pubTimestamp":1730903426,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Ionis Pharmaceuticals  reported $134 million in revenue for the quarter ended September 2024, representing a year-over-year decline of 6.9%. EPS of -$0.95 for the same period compares to -$1.03 a year ago.The reported revenue represents a surprise of +3.88% over the Zacks Consensus Estimate of $128.99 million. With the consensus EPS estimate being -$1.16, the EPS surprise was +18.10%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Revenue- Commercial Revenue- Licensing and royalty revenue: $5 million compared to the $5.51 million average estimate based on nine analysts. The reported number represents a change of -44.4% year over year.Shares of Ionis Pharmaceuticals have returned +2.7% over the past month versus the Zacks S&P 500 composite's +0.7% change. The","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"IONS":"Ionis Pharmaceuticals, Inc"},"translate_title":"与预期相比，Ionis Pharmaceuticals(IONS)第三季度收益：关键指标一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IONS":1},"content_text":"Ionis Pharmaceuticals (IONS) reported $134 million in revenue for the quarter ended September 2024, representing a year-over-year decline of 6.9%. EPS of -$0.95 for the same period compares to -$1.03 a year ago.\nThe reported revenue represents a surprise of +3.88% over the Zacks Consensus Estimate of $128.99 million. With the consensus EPS estimate being -$1.16, the EPS surprise was +18.10%.\nWhile investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.\nSince these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.\nHere is how Ionis Pharmaceuticals performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: \n\nRevenue- Commercial Revenue- Licensing and royalty revenue: $5 million compared to the $5.51 million average estimate based on nine analysts. The reported number represents a change of -44.4% year over year.\nRevenue- Research and development revenue under collaborative agreements: $45 million compared to the $49.79 million average estimate based on eight analysts. The reported number represents a change of -25% year over year.\nRevenue- Commercial Revenue- Spinraza royalties: $57 million versus $61.92 million estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a -14.9% change.\nRevenue- Commercial Revenue- Tegsedi and Waylivra revenue, net: $9 million compared to the $7.71 million average estimate based on eight analysts. The reported number represents a change of +12.5% year over year.\nRevenue- Total commercial revenue: $76 million compared to the $79.73 million average estimate based on eight analysts. The reported number represents a change of -9.5% year over year.\nRevenue- R&D Revenue- Collaborative agreement revenue: $45 million versus $33.69 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +2.3% change.\nRevenue- R&D Revenue- Amortization from upfront payments: $28 million versus $35.30 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +55.6% change.\nRevenue- R&D Revenue- WAINUA joint development revenue: $13 million versus the two-analyst average estimate of $15.75 million. The reported number represents a year-over-year change of -18.8%.\n View all Key Company Metrics for Ionis Pharmaceuticals here>>>\n\nShares of Ionis Pharmaceuticals have returned +2.7% over the past month versus the Zacks S&P 500 composite's +0.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.\n\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nIonis Pharmaceuticals, Inc. (IONS) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481393816"}